Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

This is an observational study looking at how well EGFR-TKI drugs (targeted pills that block a cancer growth signal) work in people with advanced non-small cell lung cancer that has an uncommon version of an EGFR gene mutation. Researchers want to better understand survival outcomes in this specific group. **You may be eligible if...** - You are 18 years or older - You have advanced non-squamous non-small cell lung cancer confirmed by biopsy - Your tumor has an uncommon EGFR mutation (not the most common type) **You may NOT be eligible if...** - You have a medical condition that prevents chemotherapy or targeted treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.